Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Johnson Matthey (Oxymorphone Patent)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A pharmaceutical ingredient. The patent 7,851,482 B2 for oxymorphone hydrochloride in United States, utilized as a key ingredient for the formulation of OPANA drugs which is a semi-synthetic opioid analgesic.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Other Industries
Pharmaceuticals
Primary Office
  • 25 Farringdon Street
  • 5th Floor
  • London EC4A 4AB
  • England, United Kingdom

Johnson Matthey (Oxymorphone Patent) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Johnson Matthey (Oxymorphone Patent)‘s full profile, request access.

Request full access to PitchBook

Johnson Matthey (Oxymorphone Patent) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Johnson Matthey (Oxymorphone Patent)‘s full profile, request access.

Request full access to PitchBook